Device
T4020
T4020 is a medical device with 2 clinical trials. Historical success rate of 100.0%.
Total Trials
2
Max Phase
—
Type
DEVICE
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
100%(2 trials)
Phase Distribution
Ph not_applicable
1
50%
Ph phase_3
1
50%
Phase Distribution
0
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution2 total trials
Phase 3Large-scale testing
1(50.0%)
N/ANon-phased studies
1(50.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
2
all time
Status Distribution
Completed(2)
Detailed Status
Completed2
Development Timeline
Analytics
Development Status
Total Trials
2
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 31 (50.0%)
N/A1 (50.0%)
Trials by Status
completed2100%
Recent Activity
0 active trials
Showing 2 of 2
completedphase_3
Efficacy and Safety Assessment of T4020 Versus Vehicule in Patients With Chronic Neurotrophic Keratitis or Corneal Ulcer
NCT01794312
completednot_applicable
Performance and Safety Assessment of T4020 in Managing Corneal Epithelial Defect Following Epi-off Accelerated Crosslinking
NCT02979054
Clinical Trials (2)
Showing 2 of 2 trials
NCT01794312Phase 3
Efficacy and Safety Assessment of T4020 Versus Vehicule in Patients With Chronic Neurotrophic Keratitis or Corneal Ulcer
NCT02979054Not Applicable
Performance and Safety Assessment of T4020 in Managing Corneal Epithelial Defect Following Epi-off Accelerated Crosslinking
All 2 trials loaded
Drug Details
- Intervention Type
- DEVICE
- Total Trials
- 2